MATEON THERAPEUTICS INC·4

Jun 22, 4:12 PM ET

LOAR MATTHEW M 4

4 · MATEON THERAPEUTICS INC · Filed Jun 22, 2018

Insider Transaction Report

Form 4
Period: 2018-06-20
LOAR MATTHEW M
Chief Financial Officer
Transactions
  • Award

    Employee Stock Option (Right to Buy)

    2018-06-20+500,000500,000 total
    Exercise: $0.22Exp: 2028-06-20Common Stock (500,000 underlying)
  • Award

    Employee Stock Option (Right to Buy)

    2018-06-20+250,000250,000 total
    Exercise: $0.22Exp: 2028-06-20Common Stock (250,000 underlying)
Footnotes (3)
  • [F1]Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "2017 Plan Options"), pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer.
  • [F2]The Options will vest in twelve equal monthly installments beginning one month after the date of grant.
  • [F3]Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "2015 Plan Options" and, collectively with the 2017 Plan Options, the "Options"), pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan in connection with his service as Chief Financial Officer.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION